	US 12,311,048 B2
	Crosslinked materials
Samir Mitragotri, Lexington, MA (US); Eric Spengler, Cambridge, MA (US); Douglas Levinson, Sherborn, MA (US); and Douglas R. Vogus, Cambridge, MA (US)
Assigned to Fount Bio, Inc., Cambridge, MA (US)
Appl. No. 17/289,468
Filed by Fount Bio, Inc., Cambridge, MA (US)
PCT Filed Nov. 1, 2019, PCT No. PCT/US2019/059553 § 371(c)(1), (2) Date Apr. 28, 2021, PCT Pub. No. WO2020/093022, PCT Pub. Date May 7, 2020.
Claims priority of provisional application 62/754,995, filed on Nov. 2, 2018.
Prior Publication US 2023/0165780 A1, Jun. 1, 2023
Int. Cl. A61K 8/73 (2006.01); A61K 8/44 (2006.01); A61K 8/49 (2006.01); A61K 8/81 (2006.01); A61K 8/86 (2006.01); A61Q 19/00 (2006.01); C08J 3/24 (2006.01)

CPC A61K 8/735 (2013.01) [A61K 8/44 (2013.01); A61K 8/49 (2013.01); A61K 8/8147 (2013.01); A61K 8/86 (2013.01); A61Q 19/00 (2013.01); C08J 3/24 (2013.01); A61K 2800/87 (2013.01); A61K 2800/91 (2013.01)]

13 Claims

1. A method of improving a skin attribute, wherein the method comprises forming a composition at a site below the stratum corneum, wherein the composition comprises a first crosslinkable entity comprising a hyaluronic acid (HA) polymer conjugated to a first crosslink moiety via a linker, wherein the first crosslink moiety is a cyanobenzothiazole (CBT) crosslink moiety and the linker is glycine, wherein the method further comprises topical administration of the first crosslinkable entity to a skin site, which topical administration is carried out prior to, simultaneously, or after topical administration to the skin site of a second crosslinkable entity, wherein the second crosslinkable entity comprises at least one cysteine second crosslink moiety conjugated to a polymer, wherein the skin site is abraded before, after, or simultaneously with the topical administration of one or both of the first and second crosslinkable entities.